MISSISSAUGA, Ontario, June 7, 2017 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (the "Company") today announced it received a written letter of resignation from Jason M. Aryeh stating that he resigned, effective immediately, from his position on the Board of Directors of the Company. Mr. Aryeh did not resign as a result of any current dispute or disagreement with the Company. Mr. Aryeh was a valued member of the Board during the period he served as a director.
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Mississauga, Ontario, Canada, its U.S. Headquarters is in Princeton, New Jersey and its Ireland Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
Aralez Pharmaceuticals US Inc. Contact:
Nichol L. Ochsner
Executive Director, Investor Relations & Corporate Communications
SOURCE Aralez Pharmaceuticals Inc.